Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25944734 | 0.88 | ALB (0.38) | ALBL3MBTL1FOLH1SIRT5MEN1 | |
| SCHEMBL23544192 | 0.83 | GLP1R (0.53) | GLP1R | |
| SCHEMBL23330799 | 0.82 | ALB (0.41) | ALBL3MBTL1FOLH1SIRT5MEN1 | |
| SCHEMBL26225643 | 0.79 | GLP1R (0.38) | GLP1RALBL3MBTL1FOLH1SIRT5 | |
| SCHEMBL25944862 | 0.79 | ALB (0.36) | GLP1RALBSIRT5 | |
| SCHEMBL23544195 | 0.77 | GLP1R (0.61) | GLP1RFOLH1 | |
| SCHEMBL8119857 | 0.76 | GLP1R (0.44) | GLP1RALBFOLH1SIRT5TSHR | |
| SCHEMBL22423516 | 0.76 | GLP1R (0.54) | GLP1R | |
| SCHEMBL22423517 | 0.76 | GLP1R (0.49) | GLP1RFOLH1 | |
| SCHEMBL23589786 | 0.75 | ALB (0.39) | ALBL3MBTL1FOLH1SIRT5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | MEDIKINE, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11718654-B2 | IL-2R-βγ binding compounds | MEDIKINE, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | IL2RA, IL2, IL15RA | GLP1R 317/4885ALB 1363/4885L3MBTL1 3723/4885 |
| US-11718654-B2 | IL-2R-βγ binding compounds | IL2RA, IL2, IL1RN | GLP1R 306/4885ALB 2282/4885L3MBTL1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.